Clinical trialsCompany release

Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF

🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026

Pooled, blinded 12-week data from 24 patients show 33% with improved FVC and no treatment-related serious adverse events, though the company says no treatment effect can be inferred.

Rein Therapeutics reported on 16 November 2026 preliminary pooled, blinded 12-week data from its Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis (IPF). The analysis covered 24 evaluable patients.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Rein Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Rein Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →